BioCentury
ARTICLE | Clinical News

Seciera: Ph III Emerald data

January 27, 2017 4:34 AM UTC

Top-line data from the double-blind, U.S. Phase III Emerald trial in 744 patients with dry eye disease showed that 0.09% Seciera met the primary endpoint of improving tear production as measured Schir...